**Blending Active and Passive Digital Technology Methods to Improve Symptom Monitoring in Early Psychosis**

(Brief Report)

*Matteo Cella1,2, Zhimin He1, Clare Killikelly1, Łukasz Okruszek1,3, Shon Lewis4, Til Wykes1,2*

1 - Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK.

2 - South London & Maudsley NHS Foundation Trust, Maudsley Hospital, Denmark Hill, London, UK.,

3 - Institute of Psychology, Polish Academy of Sciences, Warsaw, Poland.

4 - Division of Psychology & Mental Health, University of Manchester, Manchester, UK

Corresponding address:

Dr. Matteo Cella

Department of Psychology,

Institute of Psychiatry, Psychology & Neuroscience

King’s College London,

De Crespigny Park,

SE5 8AF

London, UK

Telephone: (+44) 020 7848 5001

**Abstract**

**Background**: Psychotic symptoms fluctuate over time and effective and regular monitoring may contribute to relapse prevention and improve long-term outcomes. In this proof-of-concept study we test the feasibility, acceptability and potential usefulness of a novel digital method assessing the association between physiological signals and psychotic symptom distress.

**Method**: Fifteen participants with first episode psychosis were asked to use a self-assessment mobile phone application for psychotic symptom monitoring for ten days while using a wrist worn device continuously recording heart rate variability (HRV) and electrodermal activity (EDA). We compared physiological activity when participants reported experiencing distressing and non-distressing psychotic symptoms.

**Results:** Participants completed on average 76% of the mobile phone symptom assessments. When reporting distressing hallucinations and delusions participants had significantly higher EDA levels and non-significant lower HRV values compared to when these symptoms were non-distressing.

**Discussion:** This study provides further evidence linking psychotic symptom’s distress, as experienced in everyday life, and autonomic deregulation. This proof-of-concept study may lead to further longer-term efforts to identify relapse biosignatures using automated methods based on passive monitoring. This method may allow for earlier interventions, contribute to improve relapse prevention and reduce symptoms interfering with recovery.

**Keywords**: Schizophrenia; Psychosis; Wearable; Autonomic; eHealth; mHealth.

**Introduction**

Relapse after the first episode of psychosis is common (Robinson et al., 1999) and it is associated with poorer recovery, increased distress, depression and suicidal thoughts (Birchwood & Spencer, 2001; Birchwood, Todd, & Jackson, 1998). Relapse prevention is therefore a highly desired outcome. Early warning signs of relapse usually comprise dysphoria and the emergence of attenuated but distressing psychotic symptoms (e.g. hearing voices), appearing over a period of typically five days (Brown, Kim, Mitchell, & Inskip, 2010; Cella, Cooper, Dymond, & Reed, 2008; Gleeson, Rawlings, Jackson, & McGorry, 2005). Evidence using ambulatory methods for tracking symptoms suggests that high levels of symptom related distress and poor coping abilities are amongst the most important factors contributing to relapse (Lardinois et al., 2007).

There is consensus that regular symptom monitoring may improve early intervention and relapse prevention, but it is not clear how often this should occur (Spaniel et al., 2008). Regular monitoring conducted by clinicians is also resource intensive and may be difficult to implement for early intervention services. It has been suggested that mobile health (mHealth) technologies could help to achieve frequent monitoring in the context of limited resources (Kumar et al., 2013; Narayan & Manji, 2016). However, mHealth current monitoring tools for psychosis require symptom self-assessment which may be deliberately avoided when experiencing more severe or distressing symptoms. Passive remote monitoring (pRMT) might provide a solution if it is associated with information on symptoms fluctuation and it is well tolerated.

There is evidence that people with psychosis have autonomic abnormalities and these are associated with psychotic symptoms and lower functioning (Bar et al., 2005; Clamor, Lincoln, Thayer, & Koenig, 2016; Fujibayashi et al., 2009). Studies suggest that people with psychosis have reduced vagal tone and heart rate variability (HRV) (Bar et al., 2005; Moon, Lee, Kim, & Hwang, 2013) and this is associated with illness chronicity (Toichi et al., 1999), low scores on the Global Assessment of Functioning (Khandoker, M. Fujibayashi, Moritani, & Palaniswami, 2010), and symptoms severity (Kim et al., 2004). Studies investigating sympathetic regulation found that people with psychosis have elevated levels of electrodermal activity, (EDA) (Zahn et al., 1997) and these are thought to be dependent from a limited parasympathetic capacity to down-regulate sympathetic activity (Montaquila, Trachik, & Bedwell, 2015).

Until recently most studies assessed the association between symptoms and physiological abnormalities under laboratory conditions. Developments in mHealth devices have now made it possible to measure autonomic parameters using non-invasive wearable devices and there is evidence of their acceptability in people with psychosis (e.g. Cella et al., 2018). Given the association between autonomic deregulation and psychotic symptoms, pRMT might help to identify increases in symptom related distress which may be of use in averting extreme symptom worsening and relapse.

This proof-of-concept study combines active and passive monitoring methods to explore the association between psychotic symptoms distress fluctuations and changes in autonomic parameters in a group of individuals with first episode psychosis. According to Montaquila et al., (Montaquila et al., 2015) we hypothesise that high levels of distress associated with hallucinations and delusions will be associated with low Heart Rate Variability (HRV) and high Electrodermal Activity (EDA).

**Method**

*Participants*

We recruited individuals under the care of early intervention teams in the South London and Maudsley NHS Foundation Trust. The inclusion criteria were: i) having experienced a psychotic episode, ii) aged between 18 and 35 years; iii) onset of psychosis within the last 12 months; iv) able to provide written informed consent.

*Measures*

Participants completed an assessment of symptoms using the Positive and Negative Syndrome Scale (PANSS) (Kay, Fiszbein, & Opler, 1987) and functioning using the Global Assessment of Functioning (GAF) (Hall, 1995). Clinical and medication information was extracted from participants’ electronic health records. Mean chlorpromazine equivalent levels for antipsychotic medications were calculated according to Woods (Woods, 2003). Then participants were instructed on how to use a wrist worn device, the Empatica E4 (https://www.empatica.com/en-gb/research/e4/). This device has sensors recording physiological and behavioural measures including heart rate, motion, electrodermal activity and skin temperature. Participants were asked to wear the device during day time (i.e. from when they wake up in the morning until they went to bed in the evening). Alongside the wrist device, participants were asked to use a mobile phone app(lication) for symptom self-assessment, called ClinTouch, developed for people with psychosis (Palmier-Claus et al., 2012a; Palmier-Claus et al., 2013). This app prompts participants at four pseudo-random times per day (between 11am to 9pm) to answer symptoms rating questions (e.g. “Have you heard a voice telling you that you are worthless today?”; “I have felt like I could read other people's thoughts”). Each participant rates up to twelve symptoms validated against the PANSS (Palmier-Claus et al., 2012b) in addition to personally relevant early warning signs using scores ranging from 1 (not present) to 7 (present). These included rating of anxiety, hallucinations, suspiciousness, depression, somatic concern, social withdrawal, hostility, conceptual disorganisation but not only. The mobile phone app allows for personalisation so that only relevant symptom rating prompts are sent to participants. For each symptom rated as present the app prompts participants to rate the associated distress level ranging from 1 to 7. A rating above three was considered indicative of a distressing symptom. All the participants in this study had hallucinations and delusions and each ClinTouch assessment asked to rate these symptoms. Participants were asked to use simultaneously ClinTouch and the E4 device for 10 consecutive days. Devices acceptability was evaluated using a questionnaire including questions on the device level of disruption to participants’ life, if the device was easy to use or stopped participants to do activities, and whether the experience of using the device was enjoyable or caused any embarrassment. This measure was used in previous studies involving people with psychosis and similar mHealth devices (e.g. Edwards, Cella, Tarrier, & Wykes, 2016).

*Analysis*

For analysis we considered samples of physiological recording collected at the time participants completed the mobile phone symptom self-assessment survey. We considered physiological recording samples of 20 minutes, from 10 minutes before the symptoms self-assessment survey trigger to 10 minutes after.

The electrodermal activity data was pre-processed for artefact using Ledalab 3.2.2 toolbox from Matlab (Benedek & Kaernbach, 2010). For each sample we used this software to extract EDA mean magnitude. HRV was computed from inter-beat intervals values using Kubios HRV software (Tarvainen, Niskanen, Lipponen, Ranta-Aho, & Karjalainen, 2014). For HRV analysis we considered the standard deviation of all normal heart beat peak interval (SDNN). This measure is considered more accurate over shorter samples (i.e. less than 1 hour) (Okruszek, Dolan, Lawrence, & Cella, 2017; Sollers, Buchanan, Mowrer, Hill, & Thayer, 2007). The E4 device also collected information on movement using a 3-axis accelerometer. From this information we computed an overall activity measure by means of a standard Euclidean metric. We used this measure as a covariate in the analysis. This is because electrodermal activity and HRV parameters are affected by the body metabolic state and controlling for activity helps to exclude physiological changes dependent on exercise and physical exertion.

We assessed the acceptability of the procedures employed in this study by considering the proportion of participants endorsing a positive rating on the acceptability feedback questionnaire items (i.e. endorsing agree on strongly agree).

We used multi-level logistic modelling with participant, our cluster variable, considered as a random-effect, while the effects of the predictors (i.e. SDNN and EDA) on the outcome variable (i.e. symptoms distress present or absent) were described as fixed effects. Analysis was conducted using the XTMELOGIT command in Stata (Version 15) (StataCorp, 2017) in line with similar studies (e.g. Edwards, Cella, Emsley, Tarrier, & Wykes, 2018; Kimhy, Myin-Germeys, Palmier-Claus, & Swendsen, 2012). The effect of predictors on the outcome, representing the regression coefficients, are expressed as Z scores and odd ratios.

**Results**

Of the fifteen participants recruited, fourteen completed the whole study. One participant withdrew after a sudden family bereavement. The participants were predominantly men (80%) with a mean age of 28.1 (SD3.8) and were all prescribed antipsychotic medications (mean chlorpromazine equivalent 238.7 (SD 174.1)). The mean PANSS positive score was 17.2 (SD 4.5), the negative was 17.9 (SD 4.78) and the general was 35.7 (SD 10.1). The GAF mean score was 48.8 (SD 9.3).

Participants completed an average of 76% of the ClinTouch assessments over the study period (i.e. on average three out of four assessments per day). All participants used the watch according to the instructions received and completed the device acceptability questionnaire. Results from the acceptability questionnaire showed that both devices were easy to use and did not have significant side effects with over 80% of the participants rating the app and the wearable device as easy to use and non-disruptive and the experience of using the devices as enjoyable.

Overall, we were able to combine data from ClinTouch and the E4 device for 157 symptoms surveys (each assessing both hallucinations and delusions). Of the completed surveys we had 47% with hallucinations rated as distressing and 45% with delusions rated as distressing. Participants rated a minimum of 6 and a maximum of 16 surveys with no significant differences in completion levels.

The model performed on delusion (Wald X2(2)=8.75, p=0.013) showed that EDA values were higher when experiencing distressing (z=2.98, p=0.003; OR=1.05; 95%CI 1.02-1.08) compared to experiencing not-distressing delusion but there was no significant difference in SDNN values (z=-0.97, p=0.3; OR=0.99; 95%CI 0.98-1.02). A similar model performed on hallucination (Wald X2(2)=8.01, p=0.02) showed that EDA values were higher when experiencing distressing (z=2.88, p=0.004; OR=1.06; 95%CI 1.02-1.09) compared to non-distressing hallucinations but there was no significant difference in SDNN (z=-0.95, p=0.34; OR=0.99; 95%CI 0.98-1.02) (see figure 1).

--------- Figure 1 about here ----------

**Discussion**

This proof-of-concept study tested the combination of active and passive monitoring methods for symptom monitoring with the longer-term aim to develop a method that can use predominantly passive information to improve symptom monitoring and contribute towards relapse prevention in psychosis. As we tested mHealth devices in people with first episode psychosis for the first time and a aim of this study was to assess acceptability and ease of use of these devices. The results support a high level of uptake and acceptability of the wearable device used and high completion levels for the mobile phone surveys.

Our results also suggest that when reporting distressing hallucinations and delusions participants had significantly higher EDA levels values compared to when these symptoms were not distressing. Associations between HRV and symptom distress were in the expected direction but did not reach a statistically significant threshold. These results replicate laboratory studies of physiological abnormalities (Kim et al., 2004) and emerging evidence associating these abnormalities with positive symptom fluctuations (Kimhy et al., 2017). Further studies consolidating the evidence on the biosignature of positive symptoms may have important implications for delivering improved and cost-effective outcomes.

With new wearable technology allowing for effortless physiological recording in real-time this study suggests that it may be possible to measure a reliable biosignature of symptom exacerbation and potentially relapse risk. With these indicators linked to a clinical service the prospect of prevention and rapid response to symptom worsening may improve substantially. However, achieving this ambitious target will require further efforts to develop data handling algorithms and machine learning tools that can produce personalised and meaningful alerts for service users and clinicians (Iniesta, Stahl, & McGuffin, 2016). Limitations of this study are the small number of service users, potential selection bias at recruitment for those more familiar with technology use, the potential confounding role of medication and variability in cardio-metabolic fitness which is difficult to control for in the analysis. However, a recent review suggests that medication is unlikely to have a strong effect on autonomic activity (Alvares, Quintana, Hickie, & Guastella, 2016).

There are other issues the field of mHealth and pRMT should consider including data handling, confidentiality and potential stigma associated with device use (Simblett et al., 2018). However, it is likely that the benefits of this technology will exceed these potential difficulties, especially in high-risk group such as people with first episode psychosis.

With increasing evidence suggesting that mHealth devices are acceptable and easy to use the focus of research now should shift to develop accurate systems for prediction based predominantly on passive monitoring information. Efforts should also be made for building the necessary evidence for devices to be recommended and used as part of routine care.

**Acknowledgements**

The authors would like to acknowledge the support of the NIHR Biomedical Research Centre in Mental Health at the South London and Maudsley Foundation Trust and the Institute of Psychiatry, Psychology and Neuroscience at King's College London. TW would also like to acknowledge her NIHR Senior Investigator award. SL and TW would like to acknowledge the UK Medical Research Council for support in the development and evaluation of ClinTouch.

Figure 1

Figure 1: Show mean Heart Rate Variability (SDNN-standard deviation of consecutive NN in milliseconds) and Electrodermal Activity (EDA in microsimens) for samples where hallucination and delusion were reported as Distressing and Non-distressing.

**References**

Alvares, G. A., Quintana, D. S., Hickie, I. B., & Guastella, A. J. (2016). Autonomic nervous system dysfunction in psychiatric disorders and the impact of psychotropic medications: a systematic review and meta-analysis. *J Psychiatry Neurosci, 41*(2), 89-104.

Bar, K. J., Letzsch, A., Jochum, T., Wagner, G., Greiner, W., & Sauer, H. (2005). Loss of efferent vagal activity in acute schizophrenia. *J Psychiatr Res, 39*(5), 519-527. doi:10.1016/j.jpsychires.2004.12.007

Benedek, M., & Kaernbach, C. (2010). A continuous measure of phasic electrodermal activity. *J Neurosci Methods, 190*(1), 80-91. doi:10.1016/j.jneumeth.2010.04.028

Birchwood, M., & Spencer, E. (2001). Early intervention in psychotic relapse. *Clin Psychol Rev, 21*(8), 1211-1226.

Birchwood, M., Todd, P., & Jackson, C. (1998). Early intervention in psychosis - The critical period hypothesis. *British Journal of Psychiatry, 172*, 53-59.

Brown, S., Kim, M., Mitchell, C., & Inskip, H. (2010). Twenty-five year mortality of a community cohort with schizophrenia. *Br J Psychiatry, 196*(2), 116-121. doi:10.1192/bjp.bp.109.067512

Cella, M., Cooper, A., Dymond, S. O., & Reed, P. (2008). The relationship between dysphoria and proneness to hallucination and delusions among young adults. *Compr Psychiatry, 49*(6), 544-550. doi:10.1016/j.comppsych.2008.02.011

Cella, M., Okruszek, L., Lawrence, M., Zarlenga, V., He, Z., & Wykes, T. (2018). Using wearable technology to detect the autonomic signature of illness severity in schizophrenia. *Schizophr Res, 195*, 537-542. doi:10.1016/j.schres.2017.09.028

Clamor, A., Lincoln, T. M., Thayer, J. F., & Koenig, J. (2016). Resting vagal activity in schizophrenia: meta-analysis of heart rate variability as a potential endophenotype. *Br J Psychiatry, 208*(1), 9-16. doi:10.1192/bjp.bp.114.160762

Edwards, C. J., Cella, M., Emsley, R., Tarrier, N., & Wykes, T. H. M. (2018). Exploring the relationship between the anticipation and experience of pleasure in people with schizophrenia: An experience sampling study. *Schizophr Res, 202*, 72-79. doi:10.1016/j.schres.2018.06.040

Edwards, C. J., Cella, M., Tarrier, N., & Wykes, T. (2016). The optimisation of experience sampling protocols in people with schizophrenia. *Psychiatry Res, 244*, 289-293. doi:10.1016/j.psychres.2016.07.048

Fujibayashi, M., Matsumoto, T., Kishida, I., Kimura, T., Ishii, C., Ishii, N., & Moritani, T. (2009). Autonomic nervous system activity and psychiatric severity in schizophrenia. *Psychiatry Clin Neurosci, 63*(4), 538-545. doi:10.1111/j.1440-1819.2009.01983.x

Gleeson, J. F., Rawlings, D., Jackson, H. J., & McGorry, P. D. (2005). Early warning signs of relapse following a first episode of psychosis. *Schizophr Res, 80*(1), 107-111. doi:10.1016/j.schres.2005.07.019

Hall, R. C. (1995). Global assessment of functioning. A modified scale. *Psychosomatics, 36*(3), 267-275. doi:10.1016/S0033-3182(95)71666-8

Iniesta, R., Stahl, D., & McGuffin, P. (2016). Machine learning, statistical learning and the future of biological research in psychiatry. *Psychol Med, 46*(12), 2455-2465. doi:10.1017/S0033291716001367

Kay, S. R., Fiszbein, A., & Opler, L. A. (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. *Schizophr Bull, 13*(2), 261-276.

Khandoker, A. H., M. Fujibayashi, Moritani, T., & Palaniswami, M. (2010). Assessing sympatho-vagal balance in schizophrenia through Tone-Entropy analysis. *Computing in Cardiology*, 69-72.

Kim, J. H., Yi, S. H., Yoo, C. S., Yang, S. A., Yoon, S. C., Lee, K. Y., . . . Kim, Y. S. (2004). Heart rate dynamics and their relationship to psychotic symptom severity in clozapine-treated schizophrenic subjects. *Prog Neuropsychopharmacol Biol Psychiatry, 28*(2), 371-378. doi:10.1016/j.pnpbp.2003.11.007

Kimhy, D., Myin-Germeys, I., Palmier-Claus, J., & Swendsen, J. (2012). Mobile assessment guide for research in schizophrenia and severe mental disorders. *Schizophr Bull, 38*(3), 386-395. doi:10.1093/schbul/sbr186

Kimhy, D., Wall, M. M., Hansen, M. C., Vakhrusheva, J., Choi, C. J., Delespaul, P., . . . Malaspina, D. (2017). Autonomic Regulation and Auditory Hallucinations in Individuals With Schizophrenia: An Experience Sampling Study. *Schizophr Bull, 43*(4), 754-763. doi:10.1093/schbul/sbw219

Kumar, S., Nilsen, W. J., Abernethy, A., Atienza, A., Patrick, K., Pavel, M., . . . Swendeman, D. (2013). Mobile health technology evaluation: the mHealth evidence workshop. *Am J Prev Med, 45*(2), 228-236. doi:10.1016/j.amepre.2013.03.017

Lardinois, M., Myin-Germeys, I., Bak, M., Mengelers, R., van Os, J., & Delespaul, P. A. (2007). The dynamics of symptomatic and non-symptomatic coping with psychotic symptoms in the flow of daily life. *Acta Psychiatr Scand, 116*(1), 71-75. doi:10.1111/j.1600-0447.2007.01022.x

Montaquila, J. M., Trachik, B. J., & Bedwell, J. S. (2015). Heart rate variability and vagal tone in schizophrenia: A review. *J Psychiatr Res, 69*, 57-66. doi:10.1016/j.jpsychires.2015.07.025

Moon, E., Lee, S. H., Kim, D. H., & Hwang, B. (2013). Comparative Study of Heart Rate Variability in Patients with Schizophrenia, Bipolar Disorder, Post-traumatic Stress Disorder, or Major Depressive Disorder. *Clin Psychopharmacol Neurosci, 11*(3), 137-143. doi:10.9758/cpn.2013.11.3.137

Narayan, V. A., & Manji, H. K. (2016). Moving from 'diagnose and treat' to 'predict and pre-empt' in neuropsychiatric disorders. *Nat Rev Drug Discov, 15*(2), 71-72. doi:10.1038/nrd.2015.20

Okruszek, L., Dolan, K., Lawrence, M., & Cella, M. (2017). The beat of social cognition: Exploring the role of heart rate variability as marker of mentalizing abilities. *Soc Neurosci, 12*(5), 489-493. doi:10.1080/17470919.2016.1244113

Palmier-Claus, J. E., Ainsworth, J., Machin, M., Barrowclough, C., Dunn, G., Barkus, E., . . . Lewis, S. W. (2012a). The feasibility and validity of ambulatory self-report of psychotic symptoms using a smartphone software application. *BMC Psychiatry, 12*, 172. doi:10.1186/1471-244X-12-172

Palmier-Claus, J. E., Ainsworth, J., Machin, M., Barrowclough, C., Dunn, G., Barkus, E., . . . Lewis, S. W. (2012b). The feasibility and validity of ambulatory self-report of psychotic symptoms using a smartphone software application. *BMC Psychiatry, 12*. doi:Artn 172

10.1186/1471-244x-12-172

Palmier-Claus, J. E., Rogers, A., Ainsworth, J., Machin, M., Barrowclough, C., Laverty, L., . . . Lewis, S. W. (2013). Integrating mobile-phone based assessment for psychosis into people's everyday lives and clinical care: a qualitative study. *BMC Psychiatry, 13*, 34. doi:10.1186/1471-244X-13-34

Robinson, D., Woerner, M. G., Alvir, J. M., Bilder, R., Goldman, R., Geisler, S., . . . Lieberman, J. A. (1999). Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. *Arch Gen Psychiatry, 56*(3), 241-247.

Simblett, S., Greer, B., Matcham, F., Curtis, H., Polhemus, A., Ferrao, J., . . . Wykes, T. (2018). Barriers to and Facilitators of Engagement With Remote Measurement Technology for Managing Health: Systematic Review and Content Analysis of Findings. *J Med Internet Res, 20*(7), e10480. doi:10.2196/10480

Sollers, J. J., 3rd, Buchanan, T. W., Mowrer, S. M., Hill, L. K., & Thayer, J. F. (2007). Comparison of the ratio of the standard deviation of the R-R interval and the root mean squared successive differences (SD/rMSSD) to the low frequency-to-high frequency (LF/HF) ratio in a patient population and normal healthy controls. *Biomed Sci Instrum, 43*, 158-163.

Spaniel, F., Vohlidka, P., Hrdlicka, J., Kozeny, J., Novak, T., Motlova, L., . . . Hoschl, C. (2008). ITAREPS: information technology aided relapse prevention programme in schizophrenia. *Schizophr Res, 98*(1-3), 312-317. doi:10.1016/j.schres.2007.09.005

Tarvainen, M. P., Niskanen, J. P., Lipponen, J. A., Ranta-Aho, P. O., & Karjalainen, P. A. (2014). Kubios HRV--heart rate variability analysis software. *Comput Methods Programs Biomed, 113*(1), 210-220. doi:10.1016/j.cmpb.2013.07.024

Toichi, M., Kubota, Y., Murai, T., Kamio, Y., Sakihama, M., Toriuchi, T., . . . Miyoshi, K. (1999). The influence of psychotic states on the autonomic nervous system in schizophrenia. *Int J Psychophysiol, 31*(2), 147-154.

Woods, S. W. (2003). Chlorpromazine equivalent doses for the newer atypical antipsychotics. *J Clin Psychiatry, 64*(6), 663-667.

Zahn, T. P., Jacobsen, L. K., Gordon, C. T., McKenna, K., Frazier, J. A., & Rapoport, J. L. (1997). Autonomic nervous system markers of psychopathology in childhood-onset schizophrenia. *Arch Gen Psychiatry, 54*(10), 904-912.